President Trump announced a historic agreement with Kodak to produce critical pharmaceutical ingredients in the United States. Under the agreement, Kodak will receive a $765 million loan to begin producing generic active pharmaceutical ingredients and key starting materials for drugs. This move is part of the administration's strategy to bring medical manufacturing back to the USA and reduce dependence on foreign nations, particularly China and India. The President also mentioned the progress of a potential COVID-19 vaccine being developed by Pfizer, and expressed his support for the use of hydroxychloroquine as a treatment for the virus. He also discussed the administration's efforts to combat the virus, including the production of medical supplies and the expansion of testing capabilities. President Trump mentioned ongoing negotiations for the next round of relief measures and expressed his desire to work on an immigration bill and reduce prescription drug prices.